Clinical correlates of circulating immune complex levels in advanced lung cancer: A discrimination analysis

B. Fekete, G. Füst, A. Pál, I. Angyal, Ágnes Jakab, Katalin Merétey, A. Falus, Katalin Török, G. Szegedi, Mária Kávai, Éva Puskás, Mária Csécsi-Nagy, T. Szabó, Ágota Lenkey, Mária Misz

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Sera from 53 patients with unresectable lung cancer were tested for the presence of immune complexes by 12 assays. 5 assays (EA rosette inhibition, ADCC inhibition, platelet aggregation, IgG and C3 concentrations in PEG precipitates) could discriminate cancer patients from healthy subjects with over 80% reliability. On the basis of 3 assays (EA-I, ADCC-I and PEG-C3) a function allowing a 100% correct classification could be formulated: -(EA-I) -0.5 (ADCC-I)+ 2.4 (PEG-C3)>69.3, i.e., results higher than 69.3 are characteristic for cancer patiens and lower than 69.3 for normal subjects. The relationship between the immune complex levels and the average survival time was not altered by sex, age, histology and treatment. None of the immune complex assays or their combination were useful for the estimation of individual life expectation.

Original languageEnglish
Pages (from-to)106-110
Number of pages5
JournalOncology
Volume40
Issue number2
DOIs
Publication statusPublished - 1983

Fingerprint

Antibody-Dependent Cell Cytotoxicity
Antigen-Antibody Complex
Lung Neoplasms
Platelet Aggregation
Neoplasms
Histology
Healthy Volunteers
Immunoglobulin G
Survival
Serum
Therapeutics

Keywords

  • Immune complexes
  • Lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clinical correlates of circulating immune complex levels in advanced lung cancer : A discrimination analysis. / Fekete, B.; Füst, G.; Pál, A.; Angyal, I.; Jakab, Ágnes; Merétey, Katalin; Falus, A.; Török, Katalin; Szegedi, G.; Kávai, Mária; Puskás, Éva; Csécsi-Nagy, Mária; Szabó, T.; Lenkey, Ágota; Misz, Mária.

In: Oncology, Vol. 40, No. 2, 1983, p. 106-110.

Research output: Contribution to journalArticle

Fekete, B, Füst, G, Pál, A, Angyal, I, Jakab, Á, Merétey, K, Falus, A, Török, K, Szegedi, G, Kávai, M, Puskás, É, Csécsi-Nagy, M, Szabó, T, Lenkey, Á & Misz, M 1983, 'Clinical correlates of circulating immune complex levels in advanced lung cancer: A discrimination analysis', Oncology, vol. 40, no. 2, pp. 106-110. https://doi.org/10.1159/000225705
Fekete, B. ; Füst, G. ; Pál, A. ; Angyal, I. ; Jakab, Ágnes ; Merétey, Katalin ; Falus, A. ; Török, Katalin ; Szegedi, G. ; Kávai, Mária ; Puskás, Éva ; Csécsi-Nagy, Mária ; Szabó, T. ; Lenkey, Ágota ; Misz, Mária. / Clinical correlates of circulating immune complex levels in advanced lung cancer : A discrimination analysis. In: Oncology. 1983 ; Vol. 40, No. 2. pp. 106-110.
@article{a669ec82e18540bf8bb4f8c6498ca961,
title = "Clinical correlates of circulating immune complex levels in advanced lung cancer: A discrimination analysis",
abstract = "Sera from 53 patients with unresectable lung cancer were tested for the presence of immune complexes by 12 assays. 5 assays (EA rosette inhibition, ADCC inhibition, platelet aggregation, IgG and C3 concentrations in PEG precipitates) could discriminate cancer patients from healthy subjects with over 80{\%} reliability. On the basis of 3 assays (EA-I, ADCC-I and PEG-C3) a function allowing a 100{\%} correct classification could be formulated: -(EA-I) -0.5 (ADCC-I)+ 2.4 (PEG-C3)>69.3, i.e., results higher than 69.3 are characteristic for cancer patiens and lower than 69.3 for normal subjects. The relationship between the immune complex levels and the average survival time was not altered by sex, age, histology and treatment. None of the immune complex assays or their combination were useful for the estimation of individual life expectation.",
keywords = "Immune complexes, Lung cancer",
author = "B. Fekete and G. F{\"u}st and A. P{\'a}l and I. Angyal and {\'A}gnes Jakab and Katalin Mer{\'e}tey and A. Falus and Katalin T{\"o}r{\"o}k and G. Szegedi and M{\'a}ria K{\'a}vai and {\'E}va Pusk{\'a}s and M{\'a}ria Cs{\'e}csi-Nagy and T. Szab{\'o} and {\'A}gota Lenkey and M{\'a}ria Misz",
year = "1983",
doi = "10.1159/000225705",
language = "English",
volume = "40",
pages = "106--110",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Clinical correlates of circulating immune complex levels in advanced lung cancer

T2 - A discrimination analysis

AU - Fekete, B.

AU - Füst, G.

AU - Pál, A.

AU - Angyal, I.

AU - Jakab, Ágnes

AU - Merétey, Katalin

AU - Falus, A.

AU - Török, Katalin

AU - Szegedi, G.

AU - Kávai, Mária

AU - Puskás, Éva

AU - Csécsi-Nagy, Mária

AU - Szabó, T.

AU - Lenkey, Ágota

AU - Misz, Mária

PY - 1983

Y1 - 1983

N2 - Sera from 53 patients with unresectable lung cancer were tested for the presence of immune complexes by 12 assays. 5 assays (EA rosette inhibition, ADCC inhibition, platelet aggregation, IgG and C3 concentrations in PEG precipitates) could discriminate cancer patients from healthy subjects with over 80% reliability. On the basis of 3 assays (EA-I, ADCC-I and PEG-C3) a function allowing a 100% correct classification could be formulated: -(EA-I) -0.5 (ADCC-I)+ 2.4 (PEG-C3)>69.3, i.e., results higher than 69.3 are characteristic for cancer patiens and lower than 69.3 for normal subjects. The relationship between the immune complex levels and the average survival time was not altered by sex, age, histology and treatment. None of the immune complex assays or their combination were useful for the estimation of individual life expectation.

AB - Sera from 53 patients with unresectable lung cancer were tested for the presence of immune complexes by 12 assays. 5 assays (EA rosette inhibition, ADCC inhibition, platelet aggregation, IgG and C3 concentrations in PEG precipitates) could discriminate cancer patients from healthy subjects with over 80% reliability. On the basis of 3 assays (EA-I, ADCC-I and PEG-C3) a function allowing a 100% correct classification could be formulated: -(EA-I) -0.5 (ADCC-I)+ 2.4 (PEG-C3)>69.3, i.e., results higher than 69.3 are characteristic for cancer patiens and lower than 69.3 for normal subjects. The relationship between the immune complex levels and the average survival time was not altered by sex, age, histology and treatment. None of the immune complex assays or their combination were useful for the estimation of individual life expectation.

KW - Immune complexes

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0020683939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020683939&partnerID=8YFLogxK

U2 - 10.1159/000225705

DO - 10.1159/000225705

M3 - Article

C2 - 6828286

AN - SCOPUS:0020683939

VL - 40

SP - 106

EP - 110

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 2

ER -